Austin Biosciences

Austin Biosciences is developing a first-of-its-kind, metabolomics-based diagnostic platform designed to transform cancer care through early detection and personalized treatment monitoring. The company's core technology, exclusively licensed from the University of Minnesota, enables sensitive screening from a simple blood draw and supports applications in therapy monitoring, recurrence detection, and drug discovery. ABS is positioning itself to address critical unmet needs in oncology by providing tools for earlier intervention and more tailored therapeutic strategies.

A novel, metabolomics-based blood test platform, exclusively licensed from the University of Minnesota, designed for early cancer detection, treatment monitoring, and recurrence surveillance.

Total raised: $230.9M

ABS competes in the liquid biopsy and multi-cancer early detection space against giants like Guardant Health, Exact Sciences/Grail, and Freenome. Its key claimed differentiation is a focus on metabolomics rather than genomics or methylation, but it must prove this approach offers superior or complementary clinical utility to gain market share.